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The mechanisms by which immunogenic tumors can avoid destruction by the
immune system are only beginning to be understood. Some antigens on tumor cells
such as the thymus-leukemia antigen (1) or the murine mammary tumor virus antigen
(2) can be modulated upon interaction with the corresponding antibodies. This
antigenic modulation makes the tumor cells resistant to complement-dependent
immune cytolysis and is usually of short duration in the absence of antibody. It seems
to be due to an epigeneticmechanism, such as lateral antigen displacement, shedding,
and/or antigen internalization. The in vivo relevance of this escape from humoral
anti-tumor immunity has not been shown yet (3) .
Here we report on a new type of modulation of a tumor-associated transplantation
antigen (TATA), which leads to the specific resistance of a chemically induced tumor
to T cell-mediated immunity. These specifically immunoresistant tumor variants will
be shown to develop during metastasis of immunosensitive cloned tumor lines in a
normal immunocompetent host . In contrast to the above antigen modulation, this
type of antigenic change is stable and inherited through over 100 subsequent tumor
cell generations, even in the absence of immune T cells. The in vivo relevance of this
type of tumor variant will be demonstrated by the results from specific immunother-
apy experiments.
Materials and Methods
Tumor Lines.
￿
ESb is a spontaneous highly metastatic variant of the chemically induced
DBA/2 lymphoma L5178Y (Eb) . It first arose in 1968 (4) and was found to differ from Eb by
(a) increased invasive capacity in vitro (5); (b) increased shedding of membrane antigens (6) ;
(c) selective binding to hepatocytes (7) ; (d) increased expression of Fcy receptors (8) ; and (e)
decreased expression of receptors for Semliki forest virus (9) . In spite of functional, morpholog-
ical, and antigenic differences, the ESb line could be shown recently to be closely related to Eb
(10). Maintenance of the tumor lines has been described (10) . Cloning was performed by
growing single cells in suspension culture in microtiter plates.
Typing of Tumor Antigens.
￿
Tumor protection experiments revealed the presence of TATA on
both Eb and ESb tumor cells. These TATA of Eb and ESb were shown to be distinct and non-
cross-reactive and could be detected in vitro with the help ofsecondary tumor-pecifc syngeneic
cytolytic T lymphocytes (CTL; 11). Cytotoxic activity was measured in a 4-h
￿
Cr release assay
as described in detail (11).
Percoll Separation of Tumor Cellsfrom Internal Organs.
￿
Tumor cells from organ metastases were
separated from host tissue cells by a newly devised technique based on isopycnic density
gradient centrifugation in 70-20% Percoll. t
' Bosslet, K., R. Ruffmann, P. Altevogt, and V. Schirrmacher. 1981. A rapid method for the isolation of
metastasizing tumor cells from internal organs with the help of isopycnic density gradient centrifugation
in Percoll. Br. J. Cancer. In press.
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Results
Development of Immunoresistant Tumor Variants during Metastasis in a Normal Syngeneic
Host. With the help ofCTL typing, we followed the expression of the specific TATA
on ESb tumor cells during the process of metastasis. 12 d after subcutaneous
inoculation of 105 ESb tumor cells into syngeneic DBA/2 mice, tumor cells were
isolated either from the local tumor or from various internal organs. In the first
experiments, the tumor cells were cleaned from host tissue by growing them out by
two passages in tissue culture. In later experiments, the tumor cells were separated
from host cells by isopycnic Percoll density gradient centrifugation and tested directly
for expression of TATA. Identical results were obtained with both methods: whereas
51Cr-labeled tumor cells from the locally growing tumor and from most internal
organs or tissues (lung, kidney, liver, bone marrow, and brain) were effectively lysed
in a 4-h cytotoxicity test with tumor-specific CTL, the tumor cells isolated from the
spleen could not be lysed.
The first experiments were performed with the uncloned ESb tumor cell population.
This population could have contained immunoresistant tumor cells, although we did
not detect a single anti-ESb CTL resistant clone among the 30 ESb clones that were
isolated. The experiments were therefore repeated with individual TATA-positive
cloned ESb cell lines. These lines were cloned twice by growing single cells in
suspension culture in microtiter plates. The results from many experiments performed
with the twice-cloned line ESb-Cl 18.1 are summarized in Table I. These cells were
inoculated subcutaneously into normal syngeneic DBA/2 mice and 12 d later, the
spleen-derived tumor cells were again immunoresistant to anti-ESb CTL (results from
10 individual experiments are shown), whereas the tumor cells from liver, lung, and
the primary tumor were specifically lysed (i .e., lysed by anti-ESb but not by anti-Eb
CTL). The spleen-derived clonal tumor cell variants were not generally resistant to
lysis by CTL because they could always be killed by anti-H-2d CTL (Table I) .
The inability of spleen-derived ESb tumor cells to be lysed by anti-ESb CTL was
due to a reduced expression or even loss of TATA as shown by the following types of
experiments. (a) These variants (ESbmet_spL) were not recognized as target cells by
anti-ESb CTL, whether they were used directly as 51Cr-labeled target cells (Fig. 1 A)
or as cold target competitors for TATA-positive ESb (ESbASC) target cells (Fig. 1 B) .
In the latter test, which measures binding rather than lysis, cold ESbAsc cells could
completely inhibit the cytotoxic reactions, whereas cold ESbmet_SPL cells did not
inhibit significantly more than the negative control of Eb ascites (EbASC) tumor cells.
(6) ESbMet_SPLvariants could not be converted to an antigen-positive line by treatment
with trypsin or neuraminidase, which suggests that the antigen was not covered up by
components of the surface coat. (c) ESbMet_SPL variants remained stable and immu-
noresistant when grown and passaged in tissue culture for >100 cell generations. (d)
In contrast to the antigen-positive ESb line, the ESbmet_SPL variant was not capable
of inducing CTL activity, which suggests that it did not express a different tumor
antigen. (e) To verify that the spleen-derived tumor line was a derivative of the
inoculated ESb line, a genetic marker, azaguanine resistance (12), was introduced
into the ESb-Cl 18.1 line. The spleen-derived variants were again specifically immu-
noresistant and carried the genetic marker (see Table I, footnote 11).
Specific Immune Escape in a TumorpreimmunizedHost.
￿
The immune status of the host
was found to influence considerably the process of generation of immunoresistantBOSSLET AND SCHIRRMACHER
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Sensitivity or Resistance ofOrgan Metastases to Specific Anti-Tumor CTL
TABLE I
65,
The metastases were derived from a twice-cloned, subcutaneously inoculated murine lymphoma, ESb-CI 18.1.
* Hosts were 2-3-mooldsyngeneic DBA/2 animals, which were either unimmunized (normal) or preimmunized (immune)
with irradiated ESbtumor cells (11); a third group consisted of T cell-deficient nude mice.
105 ESb-CI 18.1 cells were inoculated subcutaneously; 12 dlater, tumor cells were isolated from the primary tumor and
from internal organs. Cell suspensions were prepared by mechanical disruption and tumorcells separated from host cells
by isopycnic density gradient centrifugation in Percoll.2 Alternatively, tumor cells were grown up intraperitoneally in
vivo or in tissue culture. Results include data from all three separation procedures.
§ Percent specific "Crrelease after4-h coincubation ofthe isolated "Cr-labeled tumor lines with tumor-specific (anti-ESb)
or anti-H-2d (C57B1/6 anti-DBA/2) specific CTLat an effectontarget cell ratio of 40:1. The CTL were generated as
described (11) and frozen in aliquots in liquid nitrogen. Values represent mean percent cytotoxicity of tumor cells from
individual animals; SD were <5%and are mostly omitted. Specificity controls consisted of anti-Eb CTLand anti-H-2k
CTL, both ofwhich did not lyse the ESbtumor cells.
~~ Values in parentheses are data from an experiment with ESb-CI 18.1 cells that had been made azaguanine resistant (12).
Thespleen-derived tumor cells were resistant to I ug/ml azaguanine in tissue culture and thus carried the genetic marker
ofthe subcutaneously inoculated cells.
clonal tumor variants. DBA/2 mice immunized against inactivated ESb tumor cells
were previouslyfound to be only partially resistant to a challenge with live ESb tumor
cells (11) . When the tumor cells that eventually grew out from an immunized mouse
were tested for sensitivity to anti-ESb CTL, they were always found to be resistant,
regardless of whether the cells were isolated from various internal organs or from the
local site (Table I). These results demonstrate the in vivo significance of the observed
new immune escape mechanism. ESb-Cl 18.1-derived tumor cells that remained
TATA-positive and immunosensitive obviously had no chance to grow in anti-ESb-
immunized syngeneic mice. The decreased immunogenicity of ESb compared with
Eb (11) thus seems to be due to this immune escape mechanism.
The induction of immunoresistant ESb tumor variants seemed to depend on the
presence of mature T lymphocytes in the host. Spleen-derived tumor cells isolated
from nude (nu/nu) mice that had been inoculated subcutaneously with 105 ESb-CI
18.1 cells remained immunosensitive (Table I) .
Evidence against the Preexistence ofthe Immunoresistant Tumor Variants.
￿
The immunore-
sistant tumor variants were not preexistent in the original twice-cloned tumor cell
population. When ESb-Cl 18.1 cells were subjected to stringent immunoselection
procedures in vitro, no immunoresistant variants could be isolated. The cells were
coincubated twice with a 500-fold excess of specific anti-ESb CTL for 4 h. In one
experiment, no tumor cells survived, whereas in a second experiment, a small number
of cells survived, which turned out to be immunosensitive after expansion in tissue
culture. These cells were recloned and all of the 17 clones isolated were immunosen-
sitive. In contrast, when the spleen-derived tumor variant from the same tumor line
Host* Tumor cells iso-
lated from$
Percent cytotoxicity
Anti-ESb
with CTL§
Anti-H-2d
DBA/2 normal Primary tumor 51, 54, 47, 39, 42, 48, (60) 11 78, 72, 69, 64, 60, 71, (48) 11
DBA/2 normal Spleen 6, 4, 8, 1, 0, 7, 10, 2, 5, 62, 64, 60, 58, 52, 61, 47, 55,
(0) 11 (53) 11
DBA/2 normal Liver 47, 49, 51, 53, 39, 42 71, 64, 78, 72, 62, 64
DBA/2 normal Lung 54, 52, 49 72,68, 64
DBA/2ESb immune Primary tumor 7 ± 3.5 65 t 4.0
DBA/2ESb immune Spleen 0 ± 2.5 59 t 2.7
DBA/2ESb immune Liver 2 t 3 73 ± 3.8
BALB/c (nu/nu) Primary tumor 55,62 65,64
BALB/c (nu/nu) Spleen 43,46 58,63
BALB/c (nu/nu) Liver 52,41 71,63
BALB/c (nu/nu) Lung 47,44 84,72560
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Comparison of aspleen-derived tumor variant (ESbmet.sPL) with the original ESb and Eb
ascitestumor lines (ESbASC, EbAsc) in a direct cytotoxicity test (A) or acold target competition test
(B) . Responder cells (R) were derived from spleens of mice immunized against ESbASC . These were
cocultured in vitro for 5 dwith mitomycin C-treated ESbASC tumor cells as stimulator cells (S) . The
anti-ESb CTLeffector cells thus generated were washed and tested in a4-h cytotoxicity test against
10" ofthe indicated 5'Cr-labeled target cells (T5 'c') . (A) shows the percent 5'Cr release in dependency
of the ratio of effector to target cells (O, from 50 :1 to 1.25:1) ; (/) indicates the spontaneous 5'Cr
release from the three targets . (B) shows the percent specific 5'Cr release (spontaneous release
subtracted) from 5'Cr ESbASC target cells in the presence of different amounts of unlabeled tumor
cells (T`°'d) . The ratio ofanti-ESbCTLeffector cells toT5'c' cellswas 5 :1 ; the ratio of T'° 'd to
T5'cr
is indicated .
was recloned, all of the 28 clones isolated were immunoresistant . These experiments
show that under immunoselective conditions in vitro using excess anti-ESb CTL, no
immunoresistant variants could be isolated from ESb-CI 18.1 . Furthermore, cells that
were typed as either immunosensitive (from in vitro) or as immunoresistant (from in
vivo) were homogeneous in this respect (results from testing 20-40 subclones of these
lines) .
20-10-R
Discussion
Our experiments demonstrate a new type of tumor variant that can arise with a
high frequency even from carefully cloned tumor lines . The immunoresistant pheno-
type remained stable for prolonged periods in tissue culture and has not reverted so
far. In spite of this, we think it is unlikely that the variant represents a mutant within
a structural gene for the TATA . If there was a high frequency of mutation for such
a gene, we would not expect the ESbTATA to be stable for long periods of time .
However, we recently reported that the same ESbTATA from the spontaneous variant
of 1968 could be re-isolated in 1978 from the Eb line that had been transplanted in
the meantime for many years .
The type of tumor variant described here differs from the organ-selective metastatic
variants described by Fidler and Kripke (13) and Nicolson and Winkelhake (14) in
several respects : (a) whereas the immunoresistant tumor variants were not preexisting,
the organ-selective ones were suggested to be preexistent (13) ; and (b) whereas the
immunoresistant variants developed during a single process of metastasis even when
starting with cloned lines, organ-selective variants did not develop under such
conditions even when starting with a noncloned tumor population (14) . Repeated in
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vivo selection procedures (up to 10 times) were usually necessary to obtain organ-
selective metastatic tumor variants. These findings suggest either (a) that the immu-
noresistant variants arise with a much higher frequency than the organ-selective ones;
or (b) that the negative-selection pressure in the case of the immunoresistant variants
is much higher than the positive-selection pressure in the case of the organ-selective
variants; or (c) a combination ofboth. The organ-selective variants may be the result
of a random process of tumor variant generation and intensive selection by the
experimentor. In contrast, the immunoresistant variants could be the result of a
random variation process or of a specific induction process (15), followed by host
selection. The exact mechanism of the development of tumor variants that are
selectively resistant to tumor-specific CTL remains to be elucidated. A distinction
between the above alternatives would be of great significance not only for mechanisms
of immune escape but also for tumor heterogeneity, tumor progression, and metastasis
in general.
Summary
A metastasizing variant of a chemically induced lymphoma from a DBA/2 mouse
is shown to carry a distinct tumor-associated transplantation antigen (TATA), which
can be recognized by syngeneic secondary anti-tumor cytolytic T lymphocytes (CTL) .
During metastasis of twice-cloned cell lines of this tumor, variants develop that are
specifically immunoresistant to lysis by anti-tumor CTL. The variants are detected in
the spleen of normal syngeneic mice. They remain stable over long-term passage in
tissue culture. The high frequency with which these immunoresistant metastatic
variants develop was found to explain the relative ineffectiveness of specific immuni-
zation against this metastatic tumor.
Compared with organ-selective metastatic variants, the immunoresistant tumor
variants seem to arise with a much higher frequency. The change in TATA expression
described here differs from antibody-induced antigenic modulation in that it is more
stable and genetically transmitted.
Receivedfor publication 8 May 1981.
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